The landscape of dementia prognosis has evolved radically with the advent of refined biomarkers, which include amyloid PET scans, tau imaging, and blood-centered tests that may detect Alzheimer's pathology a long time in advance of indications arise. While these technological advances signify exceptional progress in comprehension neurodegenerative